Dr. Niraj Kumar Jha, Assistant Professor, Department of Biotechnology, School of Engineering and Technology (SET), Sharda University, Knowledge Park III, Greater Noida, Uttar Pradesh-201310, India, Email:
J Prev Alzheimers Dis. 2021;8(4):534-551. doi: 10.14283/jpad.2021.52.
Alzheimer's disease (AD) is a global health concern owing to its complexity, which often poses a great challenge to the development of therapeutic approaches. No single theory has yet accounted for the various risk factors leading to the pathological and clinical manifestations of dementia-type AD. Therefore, treatment options targeting various molecules involved in the pathogenesis of the disease have been unsuccessful. However, the exploration of various immunotherapeutic avenues revitalizes hope after decades of disappointment. The hallmark of a good immunotherapeutic candidate is not only to remove amyloid plaques but also to slow cognitive decline. In line with this, both active and passive immunotherapy have shown success and limitations. Recent approval of aducanumab for the treatment of AD demonstrates how close passive immunotherapy is to being successful. However, several major bottlenecks still need to be resolved. This review outlines recent successes and challenges in the pursuit of an AD vaccine.
阿尔茨海默病(AD)是一个全球性的健康问题,因为它的复杂性,这往往对治疗方法的发展构成了巨大的挑战。没有单一的理论可以解释导致痴呆型 AD 的各种风险因素。因此,针对涉及疾病发病机制的各种分子的治疗选择都没有成功。然而,经过几十年的失望之后,各种免疫治疗途径的探索又重新燃起了希望。一个好的免疫治疗候选药物的标志不仅在于清除淀粉样斑块,而且还在于减缓认知能力下降。与此一致,主动和被动免疫疗法都取得了成功和局限性。最近批准 aducanumab 用于治疗 AD 表明,被动免疫疗法已经接近成功。然而,仍有几个主要的瓶颈需要解决。本综述概述了在 AD 疫苗研究方面的最新成功和挑战。